HCPCS Level II code A9526 designates Nitrogen n-13 ammonia radiopharmaceutical for diagnostic imaging, billed per study dose (up to 40 millicuries). This tracer is used primarily in nuclear cardiology for myocardial perfusion imaging and contributes to evaluation of coronary artery disease and cardiac function. The code matters nationally as hospitals and outpatient imaging centers rely on accurate coding for coverage determinations, billing consistency, and appropriate tracking of high-cost radiopharmaceuticals.

Key payers discussed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of clinical context for use of Nitrogen n-13 ammonia, common sites of service, and the payer landscape relevant to utilization and coverage. The publication also summarizes benchmarks and policy considerations relevant to radiopharmaceutical billing, highlights common modifiers used in practice, and outlines where additional documentation and billing attention is typically required.

This summary is intended to provide a concise national view of what A9526 represents, typical settings where the service is delivered, and the payer group commonly involved in coverage and reimbursement decisions. Data not available in the input is noted where applicable in detailed sections.